MediciNova

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MediciNova and other ETFs, options, and stocks.

About MNOV

MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. 

CEO
Yuichi Iwaki
CEOYuichi Iwaki
Employees
6
Employees6
Headquarters
La Jolla, California
HeadquartersLa Jolla, California
Founded
2000
Founded2000
Employees
6
Employees6

MNOV Key Statistics

Market cap
125.27M
Market cap125.27M
Price-Earnings ratio
-12.80
Price-Earnings ratio-12.80
Dividend yield
Dividend yield
Average volume
1.44M
Average volume1.44M
High today
$2.67
High today$2.67
Low today
$2.48
Low today$2.48
Open price
$2.66
Open price$2.66
Volume
241.69K
Volume241.69K
52 Week high
$3.90
52 Week high$3.90
52 Week low
$1.17
52 Week low$1.17

Stock Snapshot

As of today, MediciNova(MNOV) shares are valued at $2.55. The company's market cap stands at 125.27M, with a P/E ratio of -12.80.

As of 2026-09-24, MediciNova(MNOV) stock has fluctuated between $2.48 and $2.67. The current price stands at $2.55, placing the stock +2.6% above today's low and -4.7% off the high.

MediciNova(MNOV) shares are trading with a volume of 241.69K, against a daily average of 1.44M.

In the last year, MediciNova(MNOV) shares hit a 52-week high of $3.90 and a 52-week low of $1.17.

In the last year, MediciNova(MNOV) shares hit a 52-week high of $3.90 and a 52-week low of $1.17.

MNOV News

Investing.com 6h
MediciNova completes double-blind phase of ALS drug trial - Investing.com

...

MediciNova completes double-blind phase of ALS drug trial - Investing.com
TipRanks 7h
MediciNova completes LPLV in Phase 2b/3 clinical trial evaluating MN-166

MediciNova (MNOV) announced the completion of the last patient, last visit in the double-blind portion of COMBAT-ALS, a Phase 2b/3 clinical trial evaluating MN-...

People also own

Based on the portfolios of people who own MNOV. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.